Deutsche Bank
ALXN

Deutsche Bank’s Alexion Pharmaceuticals ALXN Stock Holding History

Deutsche Bank’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-316
Closed -$42K – 5617
2019
Q1 		$42K Buy
316
+185
+141% +$23K ﹤0.01% 4615
2018
Q4 		$12K Sell
131
-22
-14% -$2.6K ﹤0.01% 4844
2018
Q3 		$21K Buy
153
+3
+2% +$376 ﹤0.01% 4928
2018
Q2 		$19K Hold
150
– – ﹤0.01% 5033
2018
Q1 		$16K Hold
150
– – ﹤0.01% 5054
2017
Q4 		$17K Sell
150
-709
-83% -$86.3K ﹤0.01% 4703
2017
Q3 		$120K Buy
859
+797
+1,285% +$108K ﹤0.01% 4107
2017
Q2 		$7K Buy
+62
New +$7.22K ﹤0.01% 4713
2017
Q1 		– Sell
-14
Closed -$1K – 5185
2016
Q4 		$1K Buy
+14
New +$1.71K ﹤0.01% 4858
2016
Q1 		– Sell
-896
Closed -$170K – 5410
2015
Q4 		$170K Hold
896
– – ﹤0.01% 3808
2015
Q3 		$140K Hold
896
– – ﹤0.01% 3944
2015
Q2 		$161K Buy
+896
New +$155K ﹤0.01% 3993
2015
Q1 		– Sell
-270
Closed -$49K – 6174
2014
Q4 		$49K Hold
270
– – ﹤0.01% 5136
2014
Q3 		$44K Hold
270
– – ﹤0.01% 4920
2014
Q2 		$42K Buy
+270
New +$42.6K ﹤0.01% 5010

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Deutsche Bank's ALXN Position: Q3 2021 in Review

Deutsche Bank sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,217,236 shares — an estimated $407M sold.

Deutsche Bank first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $407M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Deutsche Bank reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Deutsche Bank sold 2,217,236 Alexion Pharmaceuticals shares in Q3 2021, an estimated $407M.
  • Deutsche Bank first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Deutsche Bank's Alexion Pharmaceuticals position peaked at $407M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Deutsche Bank's 13F filing for Q3 2021, filed 4 Nov 2021.